OrthoPediatrics (NASDAQ:KIDS) Stock Price Expected to Rise, Truist Financial Analyst Says

OrthoPediatrics (NASDAQ:KIDS) had its price target raised by analysts at Truist Financial from $17.00 to $20.00 in a report issued on Thursday, MarketBeat.com reports. The firm presently has a “hold” rating on the stock. Truist Financial’s target price points to a potential upside of 4.06% from the company’s current price.

Other research analysts have also issued reports about the company. BTIG Research reaffirmed a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a report on Friday, May 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Tuesday, April 21st. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a report on Friday, April 24th. Finally, TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, OrthoPediatrics presently has a consensus rating of “Moderate Buy” and an average target price of $24.78.

OrthoPediatrics Stock Down 5.7%

Shares of KIDS opened at $19.22 on Thursday. The firm has a market cap of $493.57 million, a P/E ratio of -11.44 and a beta of 0.99. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $23.70. The firm’s 50-day simple moving average is $18.66 and its 200 day simple moving average is $17.70.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. The firm had revenue of $59.36 million during the quarter, compared to the consensus estimate of $58.28 million. On average, analysts forecast that OrthoPediatrics will post -1.13 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its stake in OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after buying an additional 452,840 shares in the last quarter. Granahan Investment Management LLC raised its position in shares of OrthoPediatrics by 35.1% in the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares in the last quarter. Wasatch Advisors LP raised its position in shares of OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares in the last quarter. Deerfield Management Company L.P. increased its stake in OrthoPediatrics by 1,153.4% in the third quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock valued at $3,597,000 after acquiring an additional 178,623 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in OrthoPediatrics by 303.3% in the fourth quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock valued at $3,542,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.